Stock Analiz

Amneal Pharmaceuticals, Inc. (AMRX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Amneal Pharmaceuticals’s revenue went from $1.0B in fiscal 2016 to $3.0B in fiscal 2025, growth of about 12.8% a year.

Net income in fiscal 2025 was $72M, a net margin of 2.4%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $3.2B and net income $133M.

Free cash flow was $270M in fiscal 2025 and positive in 8 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $1.0B162017: $1.0B172018: $1.7B182019: $1.6B192020: $2.0B202021: $2.1B212022: $2.2B222023: $2.4B232024: $2.8B242025: $3.0B25$3.0B
Net income
2016: $0162017: $0172018: -$20M182019: -$604M192020: $68M202021: $13M212022: -$271M222023: -$84M232024: -$117M242025: $72M25$72M
Free cash flow
2016: -$8M162017: $139M172018: $167M182019: -$45M192020: $323M202021: $194M212022: $19M222023: $302M232024: $243M242025: $270M25$270M
EPS (diluted)
2018: $-0.1620182019: $-2.7420192020: $0.6120202021: $0.0720212022: $-0.8620222023: $-0.4820232024: $-0.3820242025: $0.222025$0.22

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3.2B$3.0B$2.8B$2.4B$2.2B$2.1B$2.0B$1.6B$1.7B$1.0B$1.0B
Gross profit$1.3B$1.1B$1.0B$821M$785M$769M$628M$353M$716M$526M$597M
Operating income$479M$394M$249M$204M-$95M$153M$91M-$249M-$20M$245M$285M
Net income$133M$72M-$117M-$84M-$271M$13M$68M-$604M-$20M$0$0
EPS (diluted)$0.42$0.22$-0.38$-0.48$-0.86$0.07$0.61$-2.74$-0.16——
R&D$181M$186M$191M$164M$196M$202M$180M$188M$194M$171M$179M
Revenue growth—+8.1%+16.7%+8.2%+5.7%+5.1%+22.5%−2.2%+60.9%+1.5%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$181M$340M$295M$346M$65M$242M$379M$2M$250M$234M$115M
Capital spending-$92M-$70M-$52M-$43M-$46M-$48M-$56M-$47M-$83M-$95M-$123M
Free cash flow$88M$270M$243M$302M$19M$194M$323M-$45M$167M$139M-$8M
Dividends paid——————$0$0$183M$375M$201M
Buybacks——————————$5000
Stock-based pay$38M$32M$28M$27M$32M$28M$21M$22M$168M$0$0

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$282M$111M$92M$26M$248M$341M$151M$213M$74M$27M
Debt—$2.6B$2.4B$2.5B$2.7B$2.8B$2.8B$2.7B$2.7B$1.4B—
Equity—-$71M-$109M$20M$298M$360M$303M$232M$505M$0—
Total assets—$3.7B$3.5B$3.5B$3.8B$3.9B$4.0B$3.7B$4.4B$1.3B—
Shares (diluted)336M325M309M176M151M152M149M132M127M——

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin40.2%36.9%36.5%34.3%35.5%36.7%31.5%21.7%43.1%50.9%58.7%
Operating margin15.0%13.1%8.9%8.5%-4.3%7.3%4.6%-15.3%-1.2%23.7%28.0%
Net margin4.2%2.4%-4.2%-3.5%-12.2%0.6%3.4%-37.1%-1.2%0.0%0.0%
FCF margin2.8%8.9%8.7%12.6%0.8%9.3%16.2%-2.8%10.1%13.5%-0.8%
ROIC—14.1%8.5%6.5%-2.5%3.1%2.3%-6.7%-0.6%16.8%—
ROE—-101.8%107.0%-424.6%-90.7%3.6%22.4%-260.2%-3.9%——

Frequently asked questions

What is Amneal Pharmaceuticals’s annual revenue?

$3.0B in fiscal 2025 and $3.2B over the twelve months to September 30, 2026.

How much profit does Amneal Pharmaceuticals make?

Net income was $72M in fiscal 2025 (net margin 2.4%).

Is Amneal Pharmaceuticals’s revenue growing?

Yes: revenue rose 8.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.